Paige

Paige, now a part of Tempus, is trailblazing the field of oncology by leveraging the power of AI to enhance cancer discovery and treatment. Founded in 2018, this United States-based company operates at the intersection of Biopharma, Biotechnology, and Health Care. By creating a cloud-based platform, Paige reinvents the pathologist's workflow, elevating diagnostic confidence and productivity on a global level. Notably, it stands as the first company to secure FDA approval for a clinical AI application in digital pathology.

With a notable acquisition investment valued at $81.25M in August 2025, led by Tempus, Paige is strategically positioned to bolster its capabilities. Beyond diagnostics, its technology also aids pharmaceutical firms in refining treatment evaluation and creating new biomarkers for drug development, ensuring that patients receive highly customized treatment options. This positions Paige as a transformative force in precision oncology.